Where does Immunovaccine Technologies Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Immunovaccine Technologies Inc. ranks #17,771 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Immunovaccine Technologies Inc. hold?

Immunovaccine Technologies Inc. holds 16 US utility patents granted between 2015 and 2023, spanning 9 technology areas.

What is Immunovaccine Technologies Inc.'s Innovation Score?

Immunovaccine Technologies Inc. has an Innovation Score of 39.2 out of 100 (top 39% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Immunovaccine Technologies Inc. focus on?

Immunovaccine Technologies Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 16 patents, ranking #1,230 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Immunovaccine Technologies Inc.'s patent grant rate increasing or decreasing?

Immunovaccine Technologies Inc.'s recent grant velocity is +29% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Immunovaccine Technologies Inc.'s patents?

Immunovaccine Technologies Inc.'s patents average 25.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Immunovaccine Technologies Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Immunovaccine Technologies Inc.

USPTO PatentsView assignee record - 16 granted patents across 9 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Immunovaccine ranks #17,771 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 9 technology areas.

#17,771
of 49,997 US assignees by volume: Top 39%
by Innovation Score (39.2/100): 25.1
avg claims per patent: +29%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17771 · Foreign Corporation #17,771 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #17,771/49,997
PHOTO-FINISH I-TEN
CPC-NARROW A61P · 9 areas
INNOV-THIN 39.2/100
CLAIMS-DENSE 25.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +29% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: I-TEN (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Immunovaccine’s 39.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (25%) Velocity 3.8 pts (10%) Breadth 10.6 pts (27%) Claim depth 15.0 pts (38%)

Qualcomm Incorporated · highest

85
Immunovaccine · this assignee

39
3D Lighting… · lowest

7

What this shows Immunovaccine's Innovation Score is 39.2/100 (top 39% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Immunovaccine?

Each dot is one of Immunovaccine’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Immunovaccine’s own 25.1 claims/patent is ABOVE the 10.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Immunovaccine vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Immunovaccine's grants concentrate

Immunovaccine Technologies Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (3 grants) versus a trough of 1 in 2015. By volume, Immunovaccine sits between I-TEN and Inis Biotech LLC.

Immunovaccine's three-year grant acceleration

Immunovaccine Technologies Inc. shows 4 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

I-ten

16
Idera Pharmaceuti…

16
Ignion S L

16
IHS Global Design…

16
Industry Academic…

16
Infastech Intelle…

16
INI Power Systems

16
Inis Biotech

16
Immunovaccine ◀

16

What this shows Immunovaccine holds 16 patents at rank #17,768, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Immunovaccine

By rank, the assignees closest to #17,768 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Immunovaccine's primary technology class.

Immunovaccine's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 39% higher than 61% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Immunovaccine Technologies Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	6.3%
2016	1	6.3%
2018	3	18.8%
2019	2	12.5%
2020	2	12.5%
2021	3	18.8%
2022	3	18.8%
2023	1	6.3%

Which technologies does Immunovaccine Technologies Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 16

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 16

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 13

C07K - Peptides 4

Y02A - Technologies FOR Adaptation TO Climate Change 4

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

C12Y - Enzymes 2

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 2

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Immunovaccine Technologies Inc.'s patent record in context - here's where to go next.

Immunovaccine Technologies Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #17,771 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Immunovaccine Technologies Inc. against I-TEN, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.